These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8746587)

  • 21. Radiosensitization of SCCVII tumours and normal tissues by nicotinamide and carbogen: analysis by micronucleus assay.
    Ono K; Masunaga S; Akuta K; Akaboshi M; Abe M
    Radiother Oncol; 1993 Aug; 28(2):162-7. PubMed ID: 8248558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.
    Bussink J; Stratford MR; van der Kogel AJ; Folkes LK; Kaanders JH
    Radiother Oncol; 2002 Jun; 63(3):285-91. PubMed ID: 12142092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma.
    Hoskin PJ; Rojas AM; Bentzen SM; Saunders MI
    J Clin Oncol; 2010 Nov; 28(33):4912-8. PubMed ID: 20956620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of concomitant chemoradiation in locally advanced head and neck cancers.
    Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
    Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment.
    Fatigante L; Ducci F; Cartei F; Colosimo S; Marini C; Prediletto R; Danesi R; Laddaga M; Del Tacca M; Caciagli P
    Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):499-504. PubMed ID: 9112444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen.
    Sibtain A; Hill S; Goodchild K; Shah N; Saunders M; Hoskin PJ
    Radiother Oncol; 2002 Jan; 62(1):69-76. PubMed ID: 11830314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study.
    Hoskin P; Rojas A; Saunders M
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1425-31. PubMed ID: 19036531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme.
    Simon JM; Noël G; Chiras J; Hoang-Xuan K; Delattre JY; Baillet F; Mazeron JJ
    Radiother Oncol; 2003 Apr; 67(1):45-51. PubMed ID: 12758239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice.
    Sun LQ; Coucke PA; Mirimanoff RO; Buchegger F
    Radiat Res; 2001 Jan; 155(1 Pt 1):26-31. PubMed ID: 11121212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial.
    Rademakers SE; Hoogsteen IJ; Rijken PF; Terhaard CH; Doornaert PA; Langendijk JA; van den Ende P; van der Kogel AJ; Bussink J; Kaanders JH
    Head Neck; 2015 Feb; 37(2):171-6. PubMed ID: 24347430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short communication: the addition of carbogen and nicotinamide to a palliative fractionation schedule for locally advanced breast cancer.
    Pigott K; Dische S; Saunders MI
    Br J Radiol; 1995 Feb; 68(806):215-8. PubMed ID: 7537598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiotoxicity on bone marrow after 89Sr therapy radiosensitized by nicotinamide and carbogen in mice.
    Zhang Y; Zheng X; Li T; Guo Y; Hang R; Lin J; Gu W
    Nucl Med Commun; 2004 Jul; 25(7):701-4. PubMed ID: 15208497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide.
    Bussink J; Kaanders JH; Van der Kogel AJ
    Acta Oncol; 1999; 38(7):875-82. PubMed ID: 10606417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time.
    Chaplin DJ; Horsman MR; Siemann DW
    Br J Cancer; 1993 Aug; 68(2):269-73. PubMed ID: 8347481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marginal misses after postoperative intensity-modulated radiotherapy for head and neck cancer.
    Chen AM; Farwell DG; Luu Q; Chen LM; Vijayakumar S; Purdy JA
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1423-9. PubMed ID: 20656416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoradiation for advanced head and neck cancer: potential for improving results to match those of current treatment modalities for early-stage tumors--long-term results of hyperfractionated chemoradiation with carbogen breathing and anemia correction with erythropoietin.
    Villar A; Martinez JC; de Serdio JL
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1382-8. PubMed ID: 18037586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.
    Hoskin PJ; Rojas AM; Saunders MI; Bentzen SM; Motohashi KJ;
    Radiother Oncol; 2009 Apr; 91(1):120-5. PubMed ID: 18992952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Final Report of a Prospective Randomized Trial to Evaluate the Dose-Response Relationship for Postoperative Radiation Therapy and Pathologic Risk Groups in Patients With Head and Neck Cancer.
    Rosenthal DI; Mohamed ASR; Garden AS; Morrison WH; El-Naggar AK; Kamal M; Weber RS; Fuller CD; Peters LJ
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1002-1011. PubMed ID: 28721881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients.
    Laurence VM; Ward R; Dennis IF; Bleehen NM
    Br J Cancer; 1995 Jul; 72(1):198-205. PubMed ID: 7599052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks.
    Bourhis J; Dendale R; Hill C; Bosq J; Janot F; Attal P; Fortin A; Marandas P; Schwaab G; Wibault P; Malaise EP; Bobin S; Luboinski B; Eschwege F; Wilson G
    Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):471-6. PubMed ID: 8655369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.